Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kd Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma

被引：0

作者：

Wang, Tingyu ^{[1
]}

Sun, Xiuhua ^{[2
]}

Qiu, Lihua ^{[3
]}

Su, Hang ^{[4
]}

Cao, Junning ^{[5
]}

Li, Zhiming ^{[6
]}

Song, Yuqin ^{[7
]}

Zhang, Li ^{[8
]}

Li, Dengju ^{[9
]}

Wu, Huijing ^{[10
]}

Zhang, Wei ^{[11
]}

Li, Junmin ^{[12
]}

Zhou, Keshu ^{[13
]}

Zhou, Hui ^{[14
]}

Yang, Yu ^{[15
]}

Li, Zhifeng ^{[16
,17
]}

Cen, Hong ^{[18
]}

Cai, Zhen ^{[19
]}

Zhang, Zhihui ^{[20
]}

Fu, Weijun ^{[21
]}

Jie, Jin ^{[22
]}

Li, Fei ^{[23
]}

Wu, Weixin ^{[24
]}

Gu, Xuekui ^{[25
]}

Zhu, Weiliang ^{[26
]}

Liu, Lihong ^{[27
]}

Li, Zengjun ^{[1
]}

Yi, Shuhua ^{[28
]}

Bao, Hanying ^{[29
]}

Xu, Zusheng ^{[29
]}

Qiu, Lugui ^{[1
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Haihe Lab Cell Ecosyst, State Key Lab Expt Hematol,Natl Clin Res Ctr Bloo, Tianjin, Peoples R China

[2] Dalian Med Univ, Hosp 2, Dalian, Peoples R China

[3] Tianjin Med Univ, Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Key Lab Canc Prevent &, Tianjin, Peoples R China

[4] Acad Mil Med Sci, Hosp 307, Beijing, Peoples R China

[5] Fudan Univ, Dept Lymphoma, Shanghai Canc Ctr, Shanghai, Peoples R China

[6] State Key Lab Oncol South China, Guangzhou, Peoples R China

[7] Peking Univ Canc Hosp & Inst, Minist Educ, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China

[8] Sichuan Univ, West China Hosp, Chengdu, Peoples R China

[9] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Peoples R China

[10] Hubei Canc Hosp, Wuhan, Peoples R China

[11] Chinese Acad Med Sci & Peking Union Med Coll, Dept Hematol, Beijing, Peoples R China

[12] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai, Peoples R China

[13] Zhengzhou Univ, Henan Canc Hosp, Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China

[14] Cent South Univ, Xiangya Sch Med, Canc Hosp, Hunan Canc Hosp, Changsha, Peoples R China

[15] Fujian Med Univ, Tumor Hosp, Fujian Prov Canc Hosp, Fuzhou, Peoples R China

[16] Xiamen Univ, Affiliated Hosp 1, Dept Hematol, Xiamen, Peoples R China

[17] Xiamen Univ, Sch Med, Inst Hematol, Xiamen, Peoples R China

[18] Guangxi Med Univ, Tumor Hosp, Nanning, Peoples R China

[19] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou, Peoples R China

[20] Sichuan Canc Hosp & Inst, Chengdu, Peoples R China

[21] Tongji Univ, Shanghai Peoples Hosp 4, Sch Med, Shanghai, Peoples R China

[22] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China

[23] Nanchang Univ, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China

[24] Xiamen Univ, Zhongshan Hosp, Xiamen, Peoples R China

[25] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Hematol, Guangzhou, Peoples R China

[26] Southern Med Univ, Zhujiang Hosp, Guangzhou, Peoples R China

[27] Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China

[28] Tianjin Inst Hlth Sci, Tianjin, Peoples R China

[29] Shanghai Yingli Pharmaceut Co Ltd, Shanghai, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-177820

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[21] Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
Shi, Yuankai
Su, Hang
Song, Yongping
Jiang, Wenqi
Sun, Xiuhua
Qian, Wenbin
Zhang, Wei
Gao, Yuhuan
Jin, Zhengming
Zhou, Jianfeng
Jin, Chuan
Zou, Liqun
Qiu, Lugui
Li, Wei
Yang, Jianmin
Hou, Ming
Zeng, Shan
Zhang, Qingyuan
Hu, Jianda
Zhou, Hui
Xiong, Yan
Liu, Peng
LANCET HAEMATOLOGY, 2019, 6 (01): : E12 - E19
[22] Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
Wang, Michael
Rule, Simon
Zinzani, Pier Luigi
Goy, Andre
Casasnovas, Olivier
Smith, Stephen D.
Damaj, Gandhi
Doorduijn, Jeanette
Lamy, Thierry
Morschhauser, Franck
Panizo, Carlos
Shah, Bijal
Davies, Andrew
Eek, Richard
Dupuis, Jehan
Jacobsen, Eric
Kater, Arnon P.
Le Gouill, Steven
Oberic, Lucie
Robak, Taduesz
Covey, Todd
Dua, Richa
Hamdy, Ahmed
Huang, Xin
Izumi, Raquel
Patel, Priti
Rothbaum, Wayne
Slatter, J. Greg
Jurczak, Wojciech
LANCET, 2018, 391 (10121): : 659 - 667
[23] Efficacy and safety of duvelisib, a phosphoinositide 3 kinase (PI3K) δ and γ inhibitor, in Chinese patients (pts) with relapsed/refractory follicular lymphoma (R/R FL): A single-arm, open-label, multicenter, phase. clinical trial.
Zheng, Zhong
Gao, Yuhuan
Song, Yongping
Qian, Ying
Jing, Hongmei
Liu, Tingbo
Zhang, Lei
Sun, Xiuhua
Zhang, Yang
Lin, Li'e
Yao, Hongxia
Zhang, Huilai
Jin, Jie
Yang, Xiugao
Yuan, Jing
Yan, Xin
Peng, Wenjuan
Bai, Bin
Zhang, Hengyi
Zhao, Weili
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[24] Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
Bartlett, Nancy L.
Costello, Brian A.
LaPlant, Betsy R.
Ansell, Stephen M.
Kuruvilla, John G.
Reeder, Craig B.
Thye, Lim S.
Anderson, Daniel M.
Krysiak, Kilannin
Ramirez, Cody
Qi, Jing
Siegel, Barry A.
Griffith, Malachi
Griffith, Obi L.
Gomez, Felicia
Fehniger, Todd A.
BLOOD, 2018, 131 (02) : 182 - 190
[25] Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
Diefenbach, Catherine
Kahl, Brad S.
McMillan, Andrew
Briones, Javier
Banerjee, Lalita
Cordoba, Raul
Miall, Fiona
Burke, John M.
Hirata, Jamie
Jiang, Yanwen
Paulson, Joseph N.
Chang, Yi Meng
Musick, Lisa
Abrisqueta, Pau
LANCET HAEMATOLOGY, 2021, 8 (12): : E891 - E901
[26] The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study
Zelenetz, Andrew D.
Jurczak, Wojciech
Ribrag, Vincent
Linton, Kim
Collins, Graham P.
Jimenez, Javier L.
Bishton, Mark
Dholaria, Bhagirathbhai
Mengarelli, Andrea
Phillips, Tycel J.
Sungala, Nagendraprasad
Musuraca, Gerardo
Sheehy, Oonagh
Van Den Neste, Eric
Odera, Mitsuhiko
Miao, Lu
Gold, Daniel P.
Ghalie, Richard G.
Zinzani, Pier L.
HEMASPHERE, 2024, 8 (08):
[27] Tislelizumab Plus GemOx in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Single-Arm, Multi-Center Phase II Trial
Ding, Kaiyang
Liu, Hailing
Yang, Haiyan
Cao, Lei
Zhao, Xiaoli
Wu, Wei
Zhang, Xiaoyan
Wang, Li
Xu, Wei
Zhu, Huayuan
Li, Jianyong
Fan, Lei
BLOOD, 2021, 138
[28] Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
Cortes, Jorge
Perl, Alexander E.
Dohner, Hartmut
Kantarjian, Hagop
Martinelli, Giovanni
Kovacsovics, Tibor
Rousselot, Philippe
Steffen, Bjorn
Dombret, Herve
Estey, Elihu
Strickland, Stephen
Altman, Jessica K.
Baldus, Claudia D.
Burnett, Alan
Kramer, Alwin
Russell, Nigel
Shah, Neil P.
Smith, Catherine C.
Wang, Eunice S.
Ifrah, Norbert
Gammon, Guy
Trone, Denise
Lazzaretto, Deborah
Levis, Mark
LANCET ONCOLOGY, 2018, 19 (07): : 889 - 903
[29] ELARA: A phase II, single-arm, multicenter, open label trial investigating the efficacy and safety of tisagenlecleucel in adult patients with refractory/relapsed follicular lymphoma (r/r FL).
Dickinson, Michael
Popplewell, Leslie
Kolstad, Arne
Ho, Joy
Teshima, Takanori
Dreyling, Martin H.
Schuster, Stephen J.
Thieblemont, Catherine
Yateman, Nigel
Lehnhoff, Katja
Lawniczek, Tomasz
Bubuteishvili-Pacaud, Lida
Fowler, Nathan Hale
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[30] A phase II multicenter study of abexinostat, an oral histone deacetylase inhibitor, in patients with relapsed/refractory follicular lymphoma
Shi, Yuankai
Gui, Lin
Cheng, Ying
Wang, Huaqing
Cao, Junning
Li, Yufu
Yu, Yong
Gao, Yuhuan
Li, Zhenling
Shen, Jianzhen
Zhang, Lei
Zhang, Qingyuan
Pan, Qin
Wang, Zhen
Ke, Xiaoyan
He, Hesheng
Guo, Shuangshuang
Wang, Yihao
Xu, Xiaohong
Zou, Liqun
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →